Bacterial cell wall compounds as Promising targets of antimicrobial agents I. Antimicrobial peptides and lipopolyamines

Current Drug Targets

Volumn 13, Issue 9, 2012, Pages 1121-1130

  de Tejada, Guillermo Martínez ^a   Sánchez Gómez, Susana ^a   Rázquin Olazaran, Iosu ^a   Kowalski, Ina ^b   Kaconis, Yani ^b   Heinbockel, Lena ^c   Andrä, Jörg ^b   Schürholz, Tobias ^c   Hornef, Mathias ^d   Dupont, Aline ^d   Garidel, Patrick ^e   Lohner, Karl ^f   Gutsmann, Thomas ^b   David, Sunil A ^g   Brandenburg, Klaus ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b RESEARCH CENTER BORSTEL   (Germany)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^g UNIVERSITY OF KANSAS   (United States)

Author keywords

Antimicrobial peptides; Endotoxin shock; Lipopolyamines; Lipopolysaccharides; Tumor necrosis factor

Indexed keywords

AMPHOPHILE; ANTIINFECTIVE AGENT; ENDOTOXIN; LACTOFERRICIN; LIPOPOLYSACCHARIDE; LIPOTEICHOIC ACID; PEPTIDOGLYCAN; PHOSPHOLIPID; POLYAMINE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; TEICHOIC ACID;

ARTICLE; BACTERIAL CELL WALL; BACTERIAL MEMBRANE; CELL MEMBRANE; GRAM NEGATIVE BACTERIUM; IMMUNE SYSTEM; LIMULUS; NONHUMAN; OUTER MEMBRANE; VALIDITY;

AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; BACTERIA; BACTERIAL PROTEINS; CELL WALL; MOLECULAR SEQUENCE DATA; POLYAMINES;

EID: 84864550395     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802002410     Document Type: Article

References (63)

1. Springer J, Safley M, Huber S, et al. Histopathological findings in fatal novel H1N1: an autopsy case series from September-November 2009 in New Orleans, Louisiana. J La State Med Soc 2010; 162: 88-91.
2. Guillemot D. Antibiotic use in humans and bacterial resistance. Curr Opin Microbiol 1999; 2: 494-8.
3. Cross AS, Opal SM. Endotoxin's role in Gram-negative bacterial infection. Curr Opin Infect Dis 1995; 8: 156-63.
4. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67: 593-656.
5. Raetz CR, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
6. Baddiley J. Bacterial cell walls and membranes. Discovery of the teichoic acids. BioEssays 1989; 10: 207-10
7. Hayashi S, Wu HC. Lipoproteins in bacteria. J Bioenerg Biomembr 1990; 22: 451-71.
8. Andrä J, Garidel P, Majerle A, et al. Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide. Eur J Biochem 2004; 271: 2037-46.
9. Brandenburg K, Jürgens G, Müller M, Fukuoka S, Koch MHJ. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. Biol Chem 2001; 382: 1215-25.
10. Andrä J, Koch MHJ, Bartels R, Brandenburg K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin. Antimicrob Agents Chemother 2004; 48: 1593-9
11. Mesaros N, Nordmann P, Plesiat P, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007; 13: 560-78.
12. Garidel P, Brandenburg, K. Current understanding of polymyxin B applications in bacteraemia/sepsis therapy prevention: clinical, pharmaceutical, structural and mechanistic aspects. Antiinfect Agents Med Chem 2009; 8: 367-85.
13. Savage PB. Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of gram-negative bacteria. Ann Med 2001; 33: 167-71
14. Wei GX, Campagna AN, Bobek LA. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J Antimicrob Chemother 2006; 57: 1100-9.
15. Holzheimer RG. The significance of endotoxin release in experimental and clinical sepsis in surgical patients-evidence for antibiotic-induced endotoxin release? Infection 1998; 26: 77-84.
16. Kirikae T, Nakano M, Morrison DC. Antibiotic-induced endotoxin release from bacteria and its clinical significance. Microbiol Immunol 1997; 41: 285-94.
17. Andrä J, Lohner K, Blondelle SE, et al. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricinderived peptide. Biochem J 2005; 385: 135-43
18. Sanchez-Gomez S, Lamata M, Leiva J, et al. Comparative analysis of selected methods for the assessment of antimicrobial and membrane-permeabilizing activity: a case study for lactoferricin derived peptides. BMC Microbiol 2008; 8: 196
19. Sanchez-Gomez S, Japelj B, Jerala R, et al. Structural features governing the activity of lactoferricin-derived peptides that act in synergy with antibiotics against Pseudomonas aeruginosa in vitro and in vivo. Antimicrob Agents Chemother 2011; 55: 218-28.
20. Japelj B, Pristovsek P, Majerle A, Jerala R. Structural origin of endotoxin neutralization and antimicrobial activity of a lactoferrinbased peptide. J Biol Chem 2005; 280: 16955-61.
21. Japelj B, Zorko M, Majerle A, et al. The acyl group as the central element of the structural organization of antimicrobial lipopeptide. J Am Chem Soc 2007; 129: 1022-3.
22. Martinez de Tejada G, Moriyon I. The outer membranes of Brucella spp. are not barriers to hydrophobic permeants. J Bacteriol 1993; 175: 5273-5.
23. Chan C, Burrows LL, Deber CM. Alginate as an auxiliary bacterial membrane: binding of membrane-active peptides by polysaccharides. J Pept Res 2005; 65: 343-51.
24. Vaara M, Vaara T. Polycations sensitize enteric bacteria to antibiotics. Antimicrob Agents Chemother 1983; 24: 107-13.
25. Tsubery H, Ofek I, Cohen S, Fridkin M. Structure-function studies of polymyxin B nonapeptide: implications to sensitization of gramnegative bacteria. J Med Chem 2000; 43: 3085-92.
26. Vallespie MG, Glaria LA, Reyes O, Garay HE, Ferrero J, Arana MJ. Limulus antilipopolysaccharide factor-derived peptide exhibits a new immunological activity with potential applicability in infectious diseases, Clin Diagn Lab Immunol 2000; 7(4): 669-75.
27. Hoess A, Watson S, Siber GR, Liddington R. Crystal structure of an endotoxin-neutralizing protein from the horseshoe crab, Limulus anti-LPS factor, at 1.5 A resolution. EMBO J 1993; 12: 3351-6.
28. Ried C, Wahl C, Miethke T, et al. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus anti-lipopolysaccharide factor. J Biol Chem 1996; 271: 28120-7.
29. Andrä J, Garidel P, Majerle A, et al. Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide Eur J Biochem 2004: 271: 2037-46.
30. Andrä J, Lamata M, Martinez de Tejada G, Bartels R, Koch MHJ, Brandenburg K. Cyclic antimicrobial peptides based on Limulus anti-lipopolysaccharide factor for neutralization of lipopolysaccharide. Biochem Pharmacol 2004; 68: 1297-307.
31. Andrä J, Howe J, Garidel P, et al. Mechanism of interaction of optimized Limulus-derived cyclic peptides with endotoxins: thermodynamic, biophysical and microbiological analysis. Biochem J 2007; 406: 297-307.
32. Pan CY, Chao TT, Chen JC, et al. Shrimp (Penaeus monodon) anti-lipopolysaccharide factor reduces the lethality of Pseudomonas aeruginosa sepsis in mice. Int Immunopharmacol 2007; 7: 687-700.
33. Kowalski I, Kaconis Y, Andrä J, et al. Physicochemical and biological characterization of anti-endotoxin peptides and their influence on lipid properties. Protein Pept Lett 2010; 17: 1328-33.
34. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979; 76: 5939-43
35. Gutsmann T, Razquin-Olazaran I, Kowaski I, et al. New antiseptic peptides to protect against endotoxin-mediated shock. Antimicrob Agents Chemother 2010; 54: 3817-24.
36. Dankesreiter S, Hoess A, Schneider-Mergener J, Wagner H, Mietke T. Synthetic endotoxin-binding peptides block endotoxin-triggered TNF-TTTproduction by macrophages in vitro and in vivo and prevent endotoxin-mediated toxic shock. J Immunol 2000; 164: 4804-11.
37. Kaconis Y, Kowalski I, Howe J, et al. Biophysical mechanisms of endotoxin neutralization by and its specificity for cationic amphiphilic peptides. Biophys J 2011; 100: 2652-61.
38. Brandenburg K, Andrä J, Garidel P, Gutsmann T. Peptide-based treatment of sepsis. Appl Microbiol Biotechnol 2011; 90(3): 799-808.
39. Morrison DC, Jacobs DM. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 1976; 13: 813-8
40. Bhattacharjya S, David SA, Mathan VI, Balaram P. Polymyxin B nonapetide: Conformations in water and in the lipopolysaccharidebound state determined by two-dimensional NMR and molecular dynamics. Biopolymers 1997; 41: 251-65
41. David SA, Mathan VI, Balaram P. Interaction of melittin with endotoxic lipid A. Biochim Biophys Acta 1992; 1123: 269-74
42. David SA, Balaram P, Mathan VI. Interaction of basic amphiphilic polypeptide antimicrobials, Gramicidin S, Tyrocidin, and Efrapeptin, with endotoxic lipid A. Med Microbiol Lett 1993; 2: 42-7.
43. David SA, Awasthi SK, Wiese A, et al. Characterization of the interactions of a polycationic, amphiphilic, terminally branched oligopeptide with lipid A and lipopolysaccharide from the deep rough mutant of Salmonella minnesota. J Endotoxin Res 1996; 3: 369-79.
44. Bhunia A, Chua GL, Domadia PN, et al. Interactions of a designed peptide with lipopolysaccharide: Bound conformation and antiendotoxic activity. Biochem Biophys Res Commun 2008; 369: 853-7.
45. David SA, Perez L, Infante MR. Sequestration of bacterial lipopolysaccharide by bis(Args) gemini compounds. Bioorg Med Chem Lett 2002; 12: 357-60.
46. David SA, Silverstein R, Amura CR, Kielian T, Morrison DC. Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 912-9.
47. Blagbrough IS, Geall AJ, David SA. Lipopolyamines incorporating the tetraamine spermine, bound to an alkyl chain, sequester bacterial lipopolysaccharide. Bioorg Med Chem Lett 2000; 10: 1959-62.
48. Burns MR, Wood SJ, Miller KA, Nguyen T, Cromer JR, David SA. Lysine-spermine conjugates: hydrophobic polyamine amides as potent lipopolysaccharide sequestrants. Bioorg Med Chem 2005; 13: 2523-36
49. Burns MR, Jenkins SA, Wood SJ, Miller K, David SA. Structureactivity relationships in lipopolysaccharide neutralizers: design, synthesis, and biological evaluation of a 540-membered amphipathic bisamide library. J Comb Chem 2006; 8: 32-43.
50. Miller KA, Suresh Kumar EV, Wood SJ, Cromer JR, Datta A, David SA. Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines. J Med Chem 2005; 48: 2589-99.
51. Khownium K, Wood SJ, Miller KA, et al. Novel endotoxinsequestering compounds with terephthalaldehyde-bisguanylhydrazone scaffolds. Bioorg Med Chem Lett 2006; 16: 1305-8.
52. Shrestha A, Sil D, Malladi SS, Warshakoon HJ, David SA. Structure-activity relationships of lipopolysaccharide sequestration in Nalkylpolyamines. Bioorg Med Chem Lett 2009; 19: 2478-81.
53. Sil D, Shrestha A, Kimbrell MR, et al. Bound to shock: protection from lethal endotoxemic shock by a novel, nontoxic, alkylpolyamine lipopolysaccharide sequestrant. Antimicrob Agents Chemother 2007; 51: 2811-9.
54. Balakrishna R, Wood SJ, Nguyen TB, et al. Structural correlates of antibacterial and membrane-permeabilizing activities in acylpolyamines. Antimicrob Agents Chemother 2006; 50: 852-61.
55. Jackson JJ, Kropp H, Hurley JC. Influence of antibiotic class and concentration on the percentage of release of lipopolysaccharide from Escherichia coli. J Infect Dis 1994; 169: 471-2.
56. Skerlavaj B, Romeo D, Gennaro R. Rapid membrane permeabilization and inhibition of vital functions of gram-negative bacteria by bactenecins. Infect Immun 1990; 58: 3724-30.
57. Lehrer RI, Barton A, Ganz T. Concurrent assessment of inner and outer membrane permeabilization and bacteriolysis in E. coli by multiple-wavelength spectrophotometry. J Immunol Methods 1988; 108: 153-8.
58. Warshakoon HJ, Burns MR, David SA. Structure-activity relationships of antimicrobial and lipoteichoic acid-sequestering properties in polyamine sulfonamides. Antimicrob Agents Chemother 2009; 53: 57-62.
59. Mignon A, Rouquet N, Fabre M, et al. LPS challenge in Dgalactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am J Respir Crit Care Med 1999; 159: 1308-15.
60. Rittirsch D, Hoesel LM, Ward PA. The disconnect between animal models of sepsis and human sepsis. J Leukoc Biol 2007; 81(1): 137-43.
61. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-7.
62. Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Schüttler J. Coincidence of pro-and antiinflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in Tcell subsets in septic and postoperative patients. Crit Care Med 2002; 30: 1015-23.
63. Silverstein R. Galactosamine lethality model: scope and limitations. J Endotoxin Res 2004; 10: 147-62.